Fulcrum Therapeutics clinical trials we track

Check company identity source

Phase 3 2 trials

Phase 2 4 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 50 participants (planned). After: 1 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 4 Feb 2030. After: 4 Jun 2026.

Recruitment status changed

Before: Enrolling by invitation. After: Terminated.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Main Study and Extension Study - Treatment-Emergent Adverse Events. After: Measure: Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs Measure: Number of Participants With Clinically Significant Changes in Chemistry Parameters Measure: Number of Participants With Clinically Significant Changes in Hematology Parameters Measure: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters.

Check registry source